Pharmatek adds further cGMP spray drying capacity to meet demand for improved pharmaceutical solubility
Company has also installed a high pressure, precision roller compactor to further support the development of spray-dried dispersions.
Catalent Pharma Solutions is increasing spray drying capacity at its Pharmatek, San Diego, California facility with the installation of an additional GEA Niro Mobile Minor unit. The expanded capabilities are being introduced in response to market demand for solubility enhancement solutions, and are expected to be validated for cGMP use by the end of April 2017. To further support the development of spray-dried dispersions, Catalent has also installed a third Gerties Mini-Pactor at its San Diego site. A high pressure, precision roller compactor, the Mini-Pactor is expected to be validated by early May 2017.
Catalent acquired Pharmatek Laboratories in September 2016, to add extensive early-phase drug development capabilities from preclinical to clinic, bring spray drying into Catalent’s portfolio of drug formulation and delivery technologies, and expand Catalent’s capability for handling highly potent compounds.
“This is the first of several strategic investments that we have planned for the San Diego facility in the immediate future,” commented Barry Littlejohns, President of Catalent’s Drug Delivery Solutions business. He added: “Last year’s acquisition of Pharmatek, and its spray drying capabilities, enables us to provide customers with a comprehensive suite of solubility and bioavailability enhancement solutions, while complementing and expanding Catalent’s OptiForm Solution Suite platform, our science-driven parallel screening approach to identify for customers the optimal formulation pathway for poorly soluble compounds.”
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.